Amyotrophic lateral sclerosis: A consensus viewpoint on designing and implementing a clinical trial

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue 2, 2004, Pages 84-98

  Leigh, P Nigel ^a   Swash, Michael ^b   Iwasaki, Yasuo ^c   Ludolph, Albert ^d   Meininger, Vincent ^e   Miller, Robert G ^f   Mitsumoto, Hiroshi ^g   Shaw, Pamela ^h   Tashiro, Kunio ⁱ   Van Den Berg, Leonard ^j  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c TOHO UNIVERSITY   (Japan)

^d UNIVERSITY OF ULM   (Germany)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f Forbes Norris MDA/ALS Research Center   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ HOKKAIDO UNIVERSITY   (Japan)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Endpoints; Motor neuron disease; TCH346

Indexed keywords

ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARUNDIC ACID; ASCORBIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CILIARY NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; DYNACTIN; GABAPENTIN; MEMANTINE; MINOCYCLINE; NEURITE PROMOTING FACTOR; NEUROPROTECTIVE AGENT; PENTOXIFYLLINE; PERIPHERIN; PHOSPHATIDYLSERINE; PLACEBO; RILUZOLE; RNA; SOMATOMEDIN C; TCH 346; TOPIRAMATE; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XALIPRODEN; DIBENZO(B,F)OXEPIN 10 YLMETHYL METHYL PROP 2 YNYL AMINE; DIBENZO(B,F)OXEPIN-10-YLMETHYL-METHYL-PROP-2-YNYL-AMINE; OXEPINE DERIVATIVE;

AMYOTROPHIC LATERAL SCLEROSIS; BABINSKI REFLEX; CLINICAL FEATURE; CLINICAL TRIAL; CLONUS; CONSENSUS DEVELOPMENT; DAILY LIFE ACTIVITY; DECISION MAKING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; DRUG EFFICACY; DRUG INDUSTRY; DRUG USE; EPIDEMIOLOGICAL DATA; FRANCE; GENE MUTATION; GUAM; HEALTH CARE UTILIZATION; HUMAN; INCIDENCE; ITALY; METHODOLOGY; MEXICO; MOTONEURON; MOUSE; MUSCLE ATROPHY; MUSCLE HYPERTONIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REVIEW; RNA PROCESSING; SURVIVAL; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; ANIMAL; STATISTICS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES; HUMANS; OXEPINS; RILUZOLE;

EID: 3843145183     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/14660820410020187     Document Type: Review

References (117)

1. Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104-117.
2. Charcot JM. Sclerose des cordons lateraux de la moelle epiniere chez une femme hysterique atteinte de contracture permanente des quatre membres. Bull de la Societe Med des Hopit de Paris 1865: 24-35.
3. Olivares L, Esteban ES, Alter M. Mexican 'resistance' to amyotrophic lateral sclerosis. Arch Neurol 1972; 27: 397-402.
4. Rosati G, Pinna L, Granieri E et al. Studies on epidemiological, clinical and aetiological aspects of ALS disease in Sardinia, southern Italy. Acta Neurol Scand 1977; 55: 231-241.
5. Brewis M, Poskanzer DC, Rolland C, Miller H. Neurological disease in an English city. Acta Neurol Scand 1966; 42 (Suppl 24): 1-89.
6. Sorenson EJ, Stalker AP, Kurland LT, Windebank AJ. Amyotrophic lateral sclerosis in Olmsted county, Minnesota. 1925-1998. Neurology 2002; 59: 280-282.
7. Mandrioli J, Fagioli P, Merelli E, Sola P. The epidemiology of ALS in Modena, Italy. Neurology 2003; 60: 683-689.
8. Preux PM, Druet-Cabanac M, Couratier P et al. Estimation of the amyotrophic lateral sclerosis incidence by capture-recapture method in the Limousin region of France. J Clin Epidemiol 2000; 53: 1025-1029.
9. Okumura H. Epidemiological and clinical patterns of Western Pacific amyotrophic lateral sclerosis (ALS) in Guam and sporadic ALS in Rochester, Minnesota, USA and Hokkaido, Japan. A comparative study. Hokkaido Igaku Zasshi 2003; 78: 187-195 (in Japanese.).
10. Scottish Motor Neurone Disease Research Group. The Scottish motor neuron disease register: a prospective study of adult onset motor neuron disease in Scotland. Methodology, demographics and clinical features of incidence cases in 1989. J Neurol Neurosurg Psychiatry 1992; 55: 536-541.
11. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology 1999; 52: 504-509.
12. Kondo K. Epidemiology of motor neuron disease. in: PN Leigh, M Swash, eds. Motor Neuron Disease: Biology and Management. Springer-Verlag, 1995: 19.
13. Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci 2001; 191: 3-9.
14. Kurland LT, Mulder DW. Epidemiological investigations of amyotrophic lateral sclerosis: 1. Preliminary report on geographical distribution, with special reference to the Mariana Islands, including clinical and pathological observations. Neurology 1954; 4: 355-378.
15. Plato CC, Garruto RM, Fox KM, Gajdusek DC. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam: a 25-year prospective case-control study. Am J Epidemiol 1986; 124: 643-656.
16. Juergens SM, Kurland LT, Okazaki H, Mulder DW. ALS in Rochester, Minnesota, 1925-1977. Neurology 1980; 30: 463-470.
17. Durrleman S, Alperovitch A. Increasing trend of ALS in France and elsewhere: are the changes real? Neurology 1989; 39: 768-773.
18. Pavlovsky Z, Vagunda V. Apoptosis-selected methods of detection of apoptosis and associated regulatory factors on tissue sections of tumours. Cesk Patol 2003; 39: 6-10.
19. Peng L, Jiang H, Bradley C. Annexin V for flow cytometric detection of phosphatidylserine expression on lymphoma cells undergoing apoptosis. Hua Xi Yi Ke Da Xue Bao 2001; 32: 602-604 (in Chinese.).
20. Dupuis L, Gonzalez de Aguilar JL, di Scala F et al. Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 358-365.
21. Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. Neurologist 1999; 5: 63-74.
22. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.
23. Chaudhuri KR, Crump S, al-Sarraj S, Anderson V, Cavanagh J, Leigh PN. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995; 129(suppl): 11-12.
24. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi C. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15-21.
25. Househam E, Swash M. Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J Neurol Sci 2000; 180: 76-81.
26. Riviere M, Meninger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998; 55: 526-528.
27. Al-Chalabi A, Leigh PN. Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol 2000; 13: 397-405.
28. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700.
29. Shaw CE, Al Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001; 1: 69-76.
30. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819.
31. Robertson J, Kriz J, Nguyen MD, Julien JP. Pathways to motor neuron degeneration in transgenic mouse models. Biochimie 2002; 84: 1151-1160.
32. Julien JP, Beaulieu JM. Cytoskeletal abnormalities in amyotrophic lateral sclerosis: beneficial or detrimental effects? J Neurol Sci 2000; 180: 7-14.
33. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999; 58: 459-471.
34. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001; 27: 257-274.
35. Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
36. Shaw CE, Enayat ZE, Chioza BA et al. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol 1998; 43: 390-394.
37. Yang Y, Hentati A, Deng HX et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001; 29: 160-165.
38. LaMonte BH, Wallace KE, Holloway BA et al. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 2002; 34: 715-27.
39. Puls I, Jonnakuty C, LaMonte BH et al. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33: 455-456.
40. Al-Chalabi A, Andersen PM, Nilsson P et al. Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet 1999; 8: 157-164.
41. Robertson J, Doroudchi MM, Nguyen MD et al. A neurotoxic peripherin slice variant in a mouse model of ALS. J Cell Biol 2003; 160: 939-949.
42. Meyer T, Alber B, Roemer K et al. High rate of constitutional chromosomal rearrangements in apparently sporadic ALS. Neurology 2003; 60: 1348-1350.
43. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. New Engl J Med 2003; 348: 1365-1375.
44. Mattson M. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med 2003; 3: 65-94.
45. Guegan C, Przedborski S. Programmed cell death in amyotrophic lateral sclerosis. J Clin Invest 2003; 111: 153-161.
46. Przedborski S, Clarke PGH. Cell death pathways in amyotrophic lateral sclerosis. In: Shaw PJ, Strong MJ, eds. Blue Series. Motor Neuron Disorders. New York: Elsevier Science, 2003:357-377.
47. Martin LJ. Neuronal cell death in nervous system development, disease and injury. Int J Mol Med 2001; 7: 455-478.
48. Vila M, Przedborski S. Targeting programmed cell death in neurodegeneative diseases. Nat Rev Neurosci 2003; 4: 365-375.
49. Heath AM, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 2002; 26: 438-458.
50. Rizzardini M, Lupi M, Bernasconi S, Mangolini A, Cantoni L. Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid. J Neurol Sci 2003; 207: 51-58.
51. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 303-321.
52. Deng H-X, Siddique T. Transgenic mouse models and human neurodegenerative disorders. Arch Neurol 2000; 57: 1695-1702.
53. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
54. Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999; 5: 347-350.
55. Desnuelle C, Dib M, Garrel C, Favier A et al. A double-blind, placebo controlled randomised clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-tocopherol Study Group. Amyotroph Lat Scler Other Motor Neuron Disord 2001; 2: 9-18.
56. Miller RG, Moore DH, Gelinas DF et al. Phase III randomised trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843-848.
57. Groeneveld GJ, Veldink JH, van der Tweel I et al. A randomised sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437-445.
58. Shibata N. Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase-1 mutation. Neuropathol 2001; 21: 82-92.
59. Lai EC, Felice KJ, Festoff BW et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo controlled study. The North America ALS/IGF-I Study Group. Neurology 1997; 49: 1621-1630.
60. Borasio GD, Robberecht W, Leigh PN et al. A placebo controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 1998; 51: 583-586.
61. BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III). Neurology 1999; 52: 1427-1433.
62. ALS CNTF Treatment Study Group. A double-blind placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. Neurology 1996; 46: 1244-1249.
63. Miller RG, Bryan WW, Dietz MA et al. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1329-1331.
64. Miller RG, Moore D, Young LA et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996; 47: 1383-1388.
65. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group [see comments]. N Engl J Med 1994; 330: 585-591.
66. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sderosis/Riluzole Study Group II [see comments]. Lancet 1996; 347: 1425-1431.
67. Sanofi-Synthelabo Inc. Data on file.
68. Cudkowicz M. Clinical trial of topiramate in subjects with amyotrophic lateral sclerosis. Presented at 13th international symposium on ALS/MND, Melbourne, Australia, 17-19 November 2002, C29.
69. Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 43-46.
70. Savas S, Delibas N, Savas C, Sutcu R, Cindas A. Pentoxifylline reduces biochemical markers of ischaemia-reperfusion induced spinal cord injury in rabbits. Spinal Cord 2002; 40: 224-229.
71. Tateishi N, Mori T, Kagamiishi Y et al. Astrocytic activation and delayed infarct expansion after permanent focal ischaemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-)-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurological deficits. J Cereb Blood Flow Metab 2002; 22: 723-734.
72. Zhu S, Stavrovskaya IG, Drozda M et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417: 74-78.
73. Kriz J, Nguyen M, Julien J. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268.
74. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067-1070.
75. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999; 386: 735-767.
76. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9: 1397-1406.
77. Lapchak PA, Araujo DM, Song D, Zivin JA. Neuroprotection by the selective cyclooxygenase-2 inhibitor SC-236 results in improvements in behavioural deficits induced by reversible spinal cord ischaemia. Stroke 2001; 32: 1220-1225.
78. Sagot Y, Toni N, Perrelet D et al. An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motor neuron disease. Br J Pharmacol 2000; 131: 721-728.
79. Bourke SC, Shaw PJ, Gibson GJ. Respiratory function vs. sleep-disordered breathing as predictors of QOL in ALS. Neurology 2001; 57: 2040-2044.
80. Lechtzin N, Rothstein J, Clawson L, Diette GB, Wiener CM. Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 5-13.
81. Jackson CE, Rosenfeld J, Moore DH et al. A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients. J Neurol Sci 2001; 191: 75-78.
82. Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology 2003; 60: 122-123.
83. Newsom-Davis IC, Lyall RA, Leigh PN et al. The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry 2001; 71: 482-487.
84. Lyall RA, Donaldson N, Fleming T et al. A prospective study of quality of life in ALS patients treated with non-invasive ventilation. Neurology 2001; 57: 153-156.
85. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124(Pt 10): 2000-2013.
86. ALS CNTF treatment study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol 1996; 53: 141-147.
87. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996; 47(Suppl 4): S233-241.
88. Mitsumoto H, Salgado ED, Negroski D et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 1986; 36: 152-159.
89. Abe K, Takanashi M, Watanabe Y et al. Decrease in N-acetylaspartate/creatine ratio in the motor area and the frontal lobe in amyotrophic lateral sclerosis. Neuroradiology 2001; 43: 537-541.
90. de Carvalho M, Turkman A, Swash M. Motor responses evoked by transcranial magnetic stimulation and peripheral nerve stimulation in the ulnar innervation in amyotrophic lateral Sclerosis; the effect of upper and lower motor neuron lesion. J Neurol Sci 2003; 210: 83-90.
91. Shefner JM, Gooch CL. Motor unit number estimation in neurological disease. Adv Neurol 2002; 88: 33-52.
92. Olney RK. Motor unit number estimation (MUNE). Amyotroph Lat Scler 2002; 3(Suppl 1): S91-92.
93. Eisen A, Swash M. Clinical neurophysiology of ALS. Clin Neurophysiol 2001; 112: 2190-2201.
94. Piantadosi S. Clinical trials: a methodolgical perspective. John Wiley, New York 1997.
95. Gordon H, Miller RG, Moore DH. ALSFRS-R as a primary outcome measure in amyotrophic lateral sclerosis clinical trials. ALS Other Motor Neuron Disord 2003. (in press.)
96. Magnus T, Beck M, Giess R, Puis I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25: 709-714.
97. Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43: 246-70.
98. Miller R, Mitchell J, Moore D. Riluzole for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Cochrane Library, Oxford. Issue 2, 2003.
99. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328-333.
100. Sanjak M, Salachas F, FrijaOrvoen E et al. Prospective quality control of vital capacity as primary endpoint in international multicentre therapeutic trial of SR57746A (xaliproden) in amyotrophic lateral sclerosis. Ann Neurol 2000; 48: 274.
101. Coulthard-Morris L, Burks JS, Herndon RM. Rehabilitation Outcome Measures. In: Herndon RM, ed. Handbook of Neurologic Rating Scales. Demos Vermande 1997: 225-264.
102. McGuire D, Garrison L, Armon C et al. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the Sickness Impact Profile. The Syntex-Synergen ALS/CNTF Study Group. J Neurol Sci 1997; 152(Suppl 1): S18-22.
103. Jenkinson C, Peto V, Jones G, Fitzpatrick R. Interpreting change in scores on the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40). Clin Rehabil 2003; 17: 380-385.
104. Eisen A, Krieger C. ALS therapy, therapeutic trials, and neuroprotection. Amyotrophic Lateral Sclerosis - A Synthesis of Research and Clinical Practice. Cambridge University Press, 1998: 209-237.
105. Bromberg MB, Anderson F, Davidson M, Miller RG. Assessing health status quality of life in ALS: comparison of the SIP/ALS-19 with the ALS Functional Rating Scale and the Short Form-12 Health Survey. ALS CARE Study Group. Clinical Assessment, Research, and Education. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 31-37.
106. Jenkinson C, Fitzpatrick R, Swash M, Peto V. The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol 2000; 247: 835-840.
107. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology 2001; 56: 442-444.
108. Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721-728.
109. Cedarbaum JM, Stambler N, Malta E et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13-21.
110. Sorenson EJ, Barkhaus PE, Davis W et al. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology, 2003 (in press.)
111. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
112. Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neuron disease: the ALSAQ-40. J Neurol 1999; 246(Suppl 3): 16-21.
113. Jenkinson C, Fitzpatrick R. Reduced item set for the amyotrophic lateral sclerosis assessment questionnaire: development and validation of the ALSAQ-5. J Neurol Neurosurg Psychiatry 2001; 70: 70-73.
114. Hickey AM, Bury G, O'Boyle CA, Bradley F, O'Kelly FD, Shannon W. A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. BMJ 1996; 313: 29-33.
115. Munsat TL. Slowing down ALS - is this good or bad? Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl 1): S19-22.
116. Moore DH, Miller RGthe Western ALS Study Group. Improving efficiency of ALS Clinical Trials. (12th International Symposium on ALS/MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 20.
117. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS; World Federation of Neurology Research Committee on Motor Neuron Diseases. J Neurol Sci 1999; 169: 2-12.